RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication
Artículo científico (JournalArticle)
Allergic Reactions to Metamizole: Immediate and Delayed Responses
[EN] Background: Pyrazolones are the most common causes of
selective nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity.
We studied a large group of patients with immediate
and delayed selective responses to metamizole.
Methods: Patients with suspicion of hypersensitivity to metamizole
were evaluated. We verified acetylsalicylic acid tolerance
and classified patients as immediate or delayed responders
if they showed symptoms less or more than 24 h
after metamizole administration. Skin tests were performed
and if negative, a basophil activation test (BAT) was performed
on immediate responders. If it was negative, we performed
a drug provocation test (DPT) with metamizole. Results:
A total of 137 patients were included: 132 reacted
within 24 h (single NSAID-induced urticaria/angioedema/
anaphylaxis; SNIUAA) and 5 after 24 h (single NSAID-induced
delayed hypersensitivity reaction; SNIDHR). Most SNIUAA
patients developed anaphylaxis (60.60%); for SNIDHR, maculopapular
exanthema was the most frequent entity (60%).
Skin testing was positive in 62.04% of all cases and BAT in 28% of the SNIUAA patients with negative skin tests. In 5.1%
of the cases, DPT with metamizole was needed to establish
the diagnosis. In 22.62% of the cases, diagnosis was established
by consistent and unequivocal history of repeated allergic
episodes in spite of a negative skin test and BAT. Conclusions:
SNIUAA to metamizole is the most frequent type of
selective NSAID hypersensitivity, with anaphylaxis being the
most common clinical entity. It may occur within 1 h after
drug intake. SNIDHR occurs in a very low percentage of cases.
The low sensitivity of diagnostic tests may be due to incomplete
characterization of the chemical structures of metamizole
and its metabolites., The present study has been supported by the Institute of Health ‘Carlos III’ of the Ministry of Economy and Competitiveness [grants cofounded by European Regional Development Fund (ERDF), Red de Reacciones Adversas a Alergenos y Farmacos (RD12/0013/0001 and PI15/01317)] and by Consejeria de Salud de la Junta de Andalucía (PI-0463-2013).